Bicara Therapeutics公布1B期研究结果:展现深度、持久的应答与良好的耐受性安全性特征

美股速递
May 22

Bicara Therapeutics Inc 公布的最新1B期临床研究数据揭示,其试验性疗法展现出深度且持久的治疗应答,同时具备耐受性良好的安全性特征。该研究结果进一步支持了该疗法的临床开发潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10